Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

NorwayBack to Norway

Clinical trials in Tromsø – page 9

142 clinical trials in Tromsø, Norway across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Tromsø at a glance
142
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

142 trials in Tromsø

Open in trial search

Non-small cell lung cancer

Not recruiting

Study on Durvalumab and Stereotactic Body Radiotherapy for Patients with Early-Stage Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Vaestra Goetalandsregionen

Hyperoxaluria

Not recruiting

Long-Term Safety and Efficacy Study of Nedosiran Injection for Patients with Primary Hyperoxaluria

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Nedosiran
  • Sponsor:Dicerna Pharmaceuticals Inc.

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Primary adrenal insufficiency

Not recruiting

Study on Quality of Life in Patients Aged 16-80 with Primary Adrenal Insufficiency Using Hydrocortisone (Plenadren) and Cortisone

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Cortisone
  • Sponsor:Helse Bergen HF

Delirium

Not recruiting

Study on Dexmedetomidine and Clonidine Hydrochloride to Prevent Delirium in Patients Undergoing Open Heart Surgery

Registered drug
Countries:NorwayNorway
  • Participants:65+ years
  • Substances:Dexmedetomidine
  • Sponsor:Oslo University Hospital HF

Plasma cell myeloma

Not recruiting

Study on Early Treatment for Multiple Myeloma Relapse Using Carfilzomib, Bortezomib, Daratumumab, Lenalidomide, and Dexamethasone in Patients with MRD Negativity

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Oslo University Hospital HF

Neonatal alloimmune thrombocytopenia

Not recruiting

Study on the Safety and Effects of RLYB212 in Pregnant Women at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Anti-(integrin BETA-3) human monoclonal antibody
  • Sponsor:Rallybio Ipa LLC

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Muscular dystrophy

Not recruiting

Study on the Effects of Ribitol (BBP-418) in Patients with Limb Girdle Muscular Dystrophy Type 2I

Investigational
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Ribitol
  • Sponsor:ML Bio Solutions Inc.

K-ras gene mutation+2

Not recruiting

Study on Sotorasib for Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer and Comorbidities

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Sotorasib
  • Sponsor:Vestre Viken HF

Other cities in Norway

The busiest research cities in the country

All 54 cities in Norway

Clinical research in Tromsø

What the registry says about research in the country

01 Oncology Studies

Multiple clinical trials focusing on innovative cancer treatments, including research on rare cancers, hepatoblastoma, and testicular cancer. Studies explore personalized treatment approaches and drug efficacy evaluation.

  • Breast Cancer Biomarkers
  • Pediatric Liver Tumors
  • Advanced Endometrial Cancer

Novel therapeutic strategies and targeted treatments are being investigated to improve patient outcomes.

02 Neurological Disorders

Research focusing on Alzheimer's disease treatment and acute ischemic stroke management. Studies evaluate new drug comparisons and therapeutic interventions.

  • Early Alzheimer's Treatment
  • Stroke Thrombolysis
  • Cognitive Function

Emphasis on developing effective therapeutic approaches for neurodegenerative conditions.

03 Pediatric Medicine

Comprehensive studies addressing various childhood conditions, including acute wheezing, leukemia, and respiratory infections.

  • Childhood Respiratory Infections
  • Pediatric Cancer Treatment
  • Inflammatory Conditions

Focus on improving treatment outcomes in young patients through innovative therapeutic approaches.

Back to NorwayAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.